Skip to main content
. 2021 Nov 9;13(22):5601. doi: 10.3390/cancers13225601

Figure 1.

Figure 1

Graphical summary of the key topics in this review. (A) Hallmarks of immunogenicity of pediatric brain cancer. (B) Ranking of pediatric brain tumor entities according to the amount of immune cell infiltration. Subgroup ranking is related to the respective entity. Abbreviations: ETMR (embryonal tumors with multilayered rosettes), MB (medulloblastoma), ATRT (atypical teratoid rhabdoid tumor), EPN (ependymoma), HGG (high-grade glioma), LGG (low-grade glioma), GBM (glioblastoma), DIPG (diffuse intrinsic pontine glioma), AA (anaplastic astrocytoma), PFA (posterior fossa, pediatric-type), ST-RELA (supratentorial, RELA fusion), DNET (dysembryoplastic neuroepithelial tumor), PA (pilocytic astrocytoma), GG (ganglioglioma), PXA (pleomorphic xanthoastrocytoma). (C) Ranking pediatric brain tumor entities along a scale of two broadly defined immune cell infiltrate categories, namely myeloid-enriched (violet) or T cell-enriched (red) infiltration. (D) Illustration of a selection of immunotherapeutic targets evaluated in several pediatric brain tumor studies. The color code represents a qualitative evaluation. Abbreviations: PF-EPN (posterior fossa ependymoma), SP-EPN (spinal ependymoma), n. a. (not analyzed in depicted studies), * (contradicting results due to different methods used in the depicted studies). Findings in (B–D) were retrieved from [15,16,17,18,21,61,63,78,106,108,109,111] descriptively. Created with BioRender.com.